Thiabendazole for the Treatment of Strongyloidiasis in Patients with Hematologic Malignancies | Zendy

Rony Schaffel | Zendy; Márcio Nucci | Zendy; Rodrigo Portugal | Zendy; Marcia B. Castro | Zendy; Selma Baía Ferreira | Zendy; Leandro Almeida | Zendy; Nelson Spector | Zendy; Wolmar Pulcheri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Thiabendazole for the Treatment of Strongyloidiasis in Patients with Hematologic Malignancies

Author(s) -

Rony Schaffel,

Márcio Nucci,

Rodrigo Portugal,

Marcia B. Castro,

Selma Baía Ferreira,

Leandro Almeida,

Nelson Spector,

Wolmar Pulcheri

Publication year - 2000

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/314023

Subject(s) - strongyloidiasis , medicine , population , hematologic neoplasms , intensive care medicine , surgery , immunology , helminths , cancer , environmental health

A total of 21 patients with hematologic malignancies were given thiabendazole for treatment of strongyloidiasis. Fifteen patients were cured. Since there were no relapses, it is unlikely that maintenance therapy has a role in the management of strongyloidiasis in this population of patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research